Label (Lbl721621542)
Pregabalin Capsule
Product Images NDC 72162-1542
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1542). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pregabalin Fig01)
The text appears to be a chart showing the percentage of patients improved and the percentage improvement in pain from the baseline. It is not clear what the numbers correspond to or what the context is.*
Figure 2 (Pregabalin Fig02)
This is a table with information regarding the percentage of patients improved after taking Pregabalin 160mg for three days. It also includes some numbers that may indicate the improvement in pain from baseline, but it is not clear how they relate to the previous information. Some characters are not recognizable, so the text is not fully understandable.*
Figure 3 (Pregabalin Fig03)
Figure 4 (Pregabalin Fig04)
Figure 5 (Pregabalin Fig05)
The text appears to be a table that describes the dosage and improvement in pain for three different medications: Fregabalin, Pregataiin, and Placebo. The table shows the number of patients who improved after taking each medication, and the percentage improvement in pain from the baseline. However, there are some characters that are not readable, which may affect the accuracy of the information provided.*
Figure 6 (Pregabalin Fig06)
This appears to be a table or chart that shows the dosages (ranging from placebo to 600mg/day) and results of multiple studies (E1, E3, S5) for an undisclosed medication or treatment. The mention of "statistically significant vs. placebo" suggests that the medication/treatment had a positive impact on the study participants, compared to those who received a placebo. However, without more context it is not possible to provide additional information on the study or its findings.*
Figure 7 (Pregabalin Fig07)
Figure 9 (Pregabalin Fig08)
The text contains a graph showing percent improvement in pain from baseline for patients taking different doses of Pregabalin and placebo. The x-axis shows the range of improvement percentage and the y-axis shows the number of patients. The graph suggests that Pregabalin at a daily dose of 300mg and 450mg can lead to higher improvement in pain compared to placebo.*
Figure 10 (Pregabalin Fig09)
This appears to be a chart showing estimated percentages of subjects without LTR (likely an abbreviation for some medical condition) over a period of 120 days. The chart also includes two groups (Progabain and Placebo) which may have received different treatments. However, there is not enough information to fully understand the context or purpose of the chart.*
Figure 11 (Pregabalin Fig10)
Figure 12 (Pregabalin Fig11)
The text is presenting a chart that shows the percentage of subjects who improved during the course of a study. The chart displays two groups - one who received Pregabalin and one who received Placebo. The X-axis shows the measurement points at different weeks, while the Y-axis displays the percentage of subjects who improved. The percent of subjects improved at week 16 from baseline is displayed from 210 to 270. However, there seem to be some formatting issues, as parts of the chart are not displaying properly.*
Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a calculation formula for CLCT (creatinine clearance) which requires the patient's age, weight, and serum creatinine level. The formula instructs to subtract the patient's age in years from 140, then multiply the result by the patient's weight in kilograms. For female patients, the result should be multiplied by 0.85, and then further multiplied by their serum creatinine level in milligrams per deciliter (mg/dL). The final value obtained from this calculation would give the estimation of the patient's creatinine clearance (CLCT).*
Chemical Structure (Pregabalin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
